Peptide therapies for gastroparesis in diabetes
Official title: Peptide and peptidomimetic therapy for gastroparesis
Funded at Cga Therapeuticals Incorporated · NIH-11410020 · Data updated 2026-11-12
A new peptide-based treatment is being tested to help people with gastroparesis linked to diabetes by improving stomach emptying and reducing inflammation.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cga Therapeuticals Incorporated NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | September 23, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $350,195 |
| NIH project number | 1R43DK148298-01 |
| Project ID | NIH-11410020 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with diabetes who have gastroparesis or related gastric emptying delays in preclinical development stages (human applicability to be determined by future trials).
✕Less likely to help
This early Phase I work uses animal models and may not translate immediately to all patients with gastroparesis.
What this research studies
This grant funds a Phase I SBIR study to test CST and its stabilized form RI-CST in diabetic and obese mouse models of gastroparesis, focusing on how these peptides affect stomach movement, insulin sensitivity, and inflammation. The work will explore how CST and RI-CST work in disease models, aiming to understand their mechanisms and potential benefits. If successful, this could lead to safer, more effective options for managing gastroparesis symptoms in people with diabetes.
Why it matters
Potential benefit: If successful, patients could gain a new therapeutic option that improves gastric motility and metabolic health with fewer side effects.
How similar studies have gone: Preclinical data suggest CST-related therapies can improve gastric function and inflammation in diabetes models, supporting continued development.
Where this research is happening
-
Cga Therapeuticals Incorporated
San Diego, United States Active
Researchers
- Principal investigator: Mahata, Manjula — Cga Therapeuticals Incorporated
- Study coordinator: Mahata, Manjula
Related research
Other NIH-funded projects on the same topics.
-
New England Gastroparesis Consortium: Neurobiology of Gastroparesis
A national project to learn about gastroparesis in children and adults by creating a registry and gathering information from patients to understand symptoms, quality of life, and disease progression.
-
Pediatric and Young Adult Gastroparesis Registry and Disease Course
This project follows children, teens, and young adults with symptoms of gastroparesis to learn how their symptoms change over time and what factors are tied to different disease patterns.
-
Pediatric gastroparesis: building a nationwide patient registry
This grant funds a national registry to study gastroparesis and similar tummy problems in children and teens, with the goal of better understanding how the condition affects their daily lives.
-
Gut-resident macrophages and gastric function in gastroparesis
A study in people with gastroparesis to understand how gut macrophages affect stomach movement and gut barrier health, with the hope of finding new ways to treat the condition.
-
Gastric electrical stimulation for stomach pain in gastroparesis
A new approach tests how adjusting a stomach-stimulating implant may reduce pain for people with gastroparesis.
-
Prucalopride for gastroparesis in adults: a multi-site trial
A multicenter study tests a medicine called prucalopride to help adults with gastroparesis feel better and have fewer stomach symptoms.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.